BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11586103)

  • 1. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.
    Safran H; Steinhoff M; Mangray S; Rathore R; King TC; Chai L; Berzein K; Moore T; Iannitti D; Reiss P; Pasquariello T; Akerman P; Quirk D; Mass R; Goldstein L; Tantravahi U
    Am J Clin Oncol; 2001 Oct; 24(5):496-9. PubMed ID: 11586103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu.
    Safran H; Iannitti D; Ramanathan R; Schwartz JD; Steinhoff M; Nauman C; Hesketh P; Rathore R; Wolff R; Tantravahi U; Hughes TM; Maia C; Pasquariello T; Goldstein L; King T; Tsai JY; Kennedy T
    Cancer Invest; 2004; 22(5):706-12. PubMed ID: 15581051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
    Dancer J; Takei H; Ro JY; Lowery-Nordberg M
    Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
    Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1).
    Hermanová M; Lukás Z; Nenutil R; Brázdil J; Kroupová I; Kren L; Pazourková M; Růzicka M; Díte P
    Neoplasma; 2004; 51(2):77-83. PubMed ID: 15190415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.
    Villella JA; Cohen S; Smith DH; Hibshoosh H; Hershman D
    Int J Gynecol Cancer; 2006; 16(5):1897-902. PubMed ID: 17009989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?
    Latif Z; Watters AD; Dunn I; Grigor K; Underwood MA; Bartlett JM
    Eur J Cancer; 2004 Jan; 40(1):56-63. PubMed ID: 14687790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
    Hammock L; Lewis M; Phillips C; Cohen C
    Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
    Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
    Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
    Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Her-2/neu and breast cancer.
    Kaptain S; Tan LK; Chen B
    Diagn Mol Pathol; 2001 Sep; 10(3):139-52. PubMed ID: 11552716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
    JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
    Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
    Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
    Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
    Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity.
    Hsu C; Huang CL; Hsu HC; Lee PH; Wang SJ; Cheng AL
    Cancer; 2002 Jan; 94(2):415-20. PubMed ID: 11900227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
    Singer CF; Köstler WJ; Hudelist G
    Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2/Neu overexpression is a rare event in peri-ampullary cancer: assessment using the HercepTest.
    Aloysius MM; Lobo DN; Rowlands BJ; Madhusudan S; Ilyas M; Zaitoun AM
    Histopathology; 2009 Aug; 55(2):236-7. PubMed ID: 19694833
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin).
    Büchler P; Reber HA; Büchler MC; Roth MA; Büchler MW; Friess H; Isacoff WH; Hines OJ
    J Gastrointest Surg; 2001; 5(2):139-46. PubMed ID: 11331475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.